Why is Hims & Hers Health stock down 4.1% today?

Traders Union
All News
Stocks
Hims & hers health slides 4.11% today

Highlights

Hims & Hers Health updated its revenue outlook with new GLP-1 data and announced a collaboration with Novo Nordisk.
Recent earnings contributed to revised revenue projections during a period of sustained analyst attention and market selling pressure.
Shares of Hims & Hers Health fell 4.11% to $30.45, with technicals forecasting a $28.4 to $32.49 range and mild upside signals offset by buyer exhaustion.

Revenue upgrades and partnerships fail to lift prices amid selling

A report was issued following the company’s updated revenue outlook, which featured new data on GLP-1 therapeutics and highlighted increased retention along with a recent collaboration with Novo Nordisk. The most recent earnings results also contributed to the revenue projections. These announcements occurred in a period of ongoing analyst activity, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, notes that Hims & Hers Health shows limited near-term appeal despite recent collaboration headlines. He sees sustained selling pressure and warns that price action above primary moving averages is offset by weak momentum and muted MACD. Neutral momentum signals and overbought conditions suggest the stock remains vulnerable. Kharitonov views the support at $30.3 as unreliable if market skepticism persists. "Caution is warranted here, as buyers appear exhausted and further downside toward $28.4 cannot be ruled out."

Viktoras Karapetjanc, expert at Traders Union, highlights that Hims & Hers Health maintains a bullish structure after the latest upbeat revenue outlook and a strong partnership with Novo Nordisk. He believes long-term trends remain positive, with institutional sentiment supported by new therapeutics data and improved retention. Market action suggests current weakness is temporary, as fundamental triggers still point upward. "I see further growth likely once $30.73 is cleared — the market offers robust setups for continued upside."

Parshwa Turakhiya, analyst, observes that HIMS is trading in a tight corridor with buyers dominating intraday, but signals point to mild upside rather than sustained momentum. Short-term technicals like the Ichimoku Kijun and neutral momentum indicators flag a sideways pattern, while market sentiment reacts to positive news without clear direction. Turakhiya believes volatility could unlock short-lived trading opportunities if $30.73 or $30.3 is breached. "I would watch for sharp moves off these levels — quick scalps could work as sentiment shifts intraday."

Mixed momentum signals as price clings to support, faces resistance

Hims & Hers Health is trading above its 20-day and 200-day moving averages ($30.02 and $28.77), but below the 50-day moving average ($32.18), suggesting strength in the short- and long-term trends with some medium-term resistance. The nearest support is at $30.3, while the closest cap on upward price action is $30.73. The Ichimoku Kijun ($30.05) provides additional short-term support. Momentum signals are mixed: both MACD and ADX are neutral, indicating a lack of clear momentum. RSI at 52.42 and CCI at 72.21 both indicate buy conditions, pointing to mild upside, while Stochastic RSI is neutral. Bull/Bear Power (BBP) at 1.71 signals buyers dominate intraday but warns of a potential overbought state. The Awesome Oscillator (AO) shows a strong buy, reinforcing underlying strength. Intraday volatility stands at 5.79%. There is clear pressure after the open, and momentum signals remain mildly bullish but offset by signs of buyer exhaustion.

Earlier, analysts noted that Hims & Hers Health was contending with operational and regulatory risks amid mixed—but generally constructive—technical momentum. The latest developments introduce updated revenue projections and new partnerships, but with persistent selling pressure and mixed momentum signals, traders should monitor $30.73 as a key resistance level for any potential shift toward renewed upside.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.